Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

English Adalimumab Tender Marks Progress, But Is Not Perfect

Executive Summary

An English adalimumab tender in effect from 1 December last year aided industry sustainability by awarding deals to multiple biosimilar suppliers. But there is still room for improvement, the BBA’s Warwick Smith believes.

You may also be interested in...



UK Could Become ‘World Leader’ On Biosimilar Regulation

The UK is putting itself in a position to play a leading role in global biosimilars regulation, thanks to a proposed new registration pathway that will not require comparative efficacy data, delegates to a Westminster Health Forum online conference heard earlier today.

BGMA’s Smith Reflects On 25 Years Of Progress

As Warwick Smith steps down after 25 years as leader of the British Generic Manufacturers Association, he talks about how far the country’s off-patent industry has come over the last quarter-century – including the acceptance of generics, the advent of biosimilars, and how freedom of pricing has helped to keep costs low while maintaining sustainable pricing – in the first part of an exclusive interview with Generics Bulletin.

Awareness Rate For Biosimilars Goes Up To 90%

An ASBM survey of 575 biologic prescribers in six western European countries has found that 90% of physicians are familiar with biosimilars, compared to 76% in 2013. The results were presented and discussed at the 2019 ESMO Congress.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel